Advertisement

Chronische Nierenerkrankung – eine kardiovaskuläre Höchstrisikokonstellation

  • T. SpeerEmail author
  • S. J. Schunk
  • D. Fliser
Schwerpunkt: Herz und Niere
  • 92 Downloads

Zusammenfassung

Die chronische Nierenerkrankung ist mit einer erhöhten kardiovaskulären Morbidität und Mortalität assoziiert. Ursächlich hierfür ist zum einen die hohe Prävalenz von traditionellen kardiovaskulären Risikofaktoren wie arterieller Hypertonie und Diabetes mellitus bei Patienten mit Nierenerkrankung, zum anderen sogenannte nichttraditionelle – niereninsuffizienzspezifische – kardiovaskuläre Risikofaktoren. Hierzu gehören eine vaskuläre Kalzifikation, Urämietoxine, die urämische Dyslipidämie sowie Inflammation und oxidativer Stress. Deshalb kommt der Primär- und Sekundärprävention kardiovaskulärer Erkrankungen in der Nephrologie eine zentrale Rolle zu. Hierzu gehören eine optimale Blutdruck- und Blutzuckereinstellung, die Therapie der Dyslipidämie und lebensstilmodifizierende Faktoren wie Gewichtsreduktion und Nikotinkarenz.

Schlüsselwörter

Kardiovaskuläre Erkrankungen, Prävention Arterielle Hypertonie Diabetes mellitus Dyslipidämien Oxidativer Stress 

Chronic kidney disease—a cardiovascular high-risk constellation

Abstract

Chronic kidney disease (CKD) is associated with substantial cardiovascular morbidity and mortality. This is mediated by the high prevalence of traditional cardiovascular risk factors in patients with CKD such as arterial hypertension and diabetes mellitus, but also by the presence of CKD-specific so-called nontraditional cardiovascular risk factors such as vascular calcification, uremic toxins, uremic dyslipidemia as well as inflammation and oxidative stress. Therefore, the primary and secondary prevention of cardiovascular disease represents an integral part of nephrology. This entails optimal control of blood pressure and diabetes, therapy of the uremic dyslipidemia as well as lifestyle-modifying factors such as weight reduction and smoking cessation.

Keywords

Cardiovascular diseases, prevention Hypertension, arterial Diabetes mellitus Dyslipidemias Oxidative stress 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

T. Speer, S.J. Schunk und D. Fliser geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRefGoogle Scholar
  2. 2.
    Ali S, Dave N, Virani SS et al (2019) Primary and secondary prevention of cardiovascular disease in patients with chronic kidney disease. Curr Atheroscler Rep 21:32CrossRefPubMedGoogle Scholar
  3. 3.
    Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37:2999–3058CrossRefPubMedGoogle Scholar
  4. 4.
    Charytan DM, Sabatine MS, Pedersen TR et al (2019) Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol 73:2961–2970CrossRefPubMedGoogle Scholar
  5. 5.
    Cheung AK, Rahman M, Reboussin DM et al (2017) Effects of intensive BP control in CKD. J Am Soc Nephrol 28:2812–2823CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cholesterol Treatment Trialists C, Herrington WG, Emberson J et al (2016) Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 4:829–839CrossRefGoogle Scholar
  7. 7.
    Drueke TB, Massy ZA (2010) Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 6:723–735CrossRefPubMedGoogle Scholar
  8. 8.
    Fried LF, Emanuele N, Zhang JH et al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369:1892–1903CrossRefPubMedGoogle Scholar
  9. 9.
    Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382:339–352CrossRefGoogle Scholar
  10. 10.
    Group AS, Cushman WC, Evans GW et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585CrossRefGoogle Scholar
  11. 11.
    Group SC, Link E, Parish S et al (2008) SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359:789–799CrossRefGoogle Scholar
  12. 12.
    Group SR, Wright JT Jr., Williamson JD et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116CrossRefGoogle Scholar
  13. 13.
    Holy EW, Akhmedov A, Speer T et al (2016) Carbamylated low-density lipoproteins induce a prothrombotic state via LOX-1: impact on arterial thrombus formation in vivo. J Am Coll Cardiol 68:1664–1676CrossRefPubMedGoogle Scholar
  14. 14.
    KDIGO (2013) 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150CrossRefGoogle Scholar
  15. 15.
    Knauf F, Brewer JR, Flavell RA (2019) Immunity, microbiota and kidney disease. Nat Rev Nephrol 15:263–274CrossRefPubMedGoogle Scholar
  16. 16.
    Mann JFE, Orsted DD, Brown-Frandsen K et al (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377:839–848CrossRefPubMedGoogle Scholar
  17. 17.
    Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657CrossRefPubMedGoogle Scholar
  19. 19.
    Ortiz A, Covic A, Fliser D et al (2014) Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 383:1831–1843CrossRefPubMedGoogle Scholar
  20. 20.
    Palmer SC, Craig JC, Navaneethan SD et al (2012) Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 157:263–275CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ridker PM, MacFadyen JG, Glynn RJ et al (2018) Inhibition of Interleukin-1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol 71:2405–2414CrossRefPubMedGoogle Scholar
  22. 22.
    Saran R, Robinson B, Abbott KC et al (2019) US renal data system 2018 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 73:A7–A8CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Speer T, Owala FO, Holy EW et al (2014) Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J 35:3021–3032CrossRefPubMedGoogle Scholar
  24. 24.
    Speer T, Rohrer L, Blyszczuk P et al (2013) Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor‑2. Immunity 38:754–768CrossRefPubMedGoogle Scholar
  25. 25.
    Speer T, Zewinger S, Fliser D (2013) Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrol Dial Transplant 28:2456–2463CrossRefPubMedGoogle Scholar
  26. 26.
    Speer T, Zewinger S, Kleber ME et al (2014) HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 25:1073–1082CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Tobe SW, Clase CM, Gao P et al (2011) Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 123:1098–1107CrossRefGoogle Scholar
  28. 28.
    Toth PP, Dwyer JP, Cannon CP et al (2018) Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 93:1397–1408CrossRefPubMedGoogle Scholar
  29. 29.
    Turin TC, Tonelli M, Manns BJ et al (2012) Chronic kidney disease and life expectancy. Nephrol Dial Transplant 27:3182–3186CrossRefPubMedGoogle Scholar
  30. 30.
    Verbeke F, Lindley E, Van Bortel L et al (2014) A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant 29:490–496CrossRefPubMedGoogle Scholar
  31. 31.
    Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334CrossRefPubMedGoogle Scholar
  32. 32.
    Wanner C, Tonelli M, Kidney Disease (2014) KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85:1303–1309CrossRefPubMedGoogle Scholar
  33. 33.
    Xie X, Liu Y, Perkovic V et al (2016) Renin-Angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67:728–741CrossRefGoogle Scholar
  34. 34.
    Zewinger S, Schumann T, Fliser D et al (2016) Innate immunity in CKD-associated vascular diseases. Nephrol Dial Transplant 31:1813–1821CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Innere Medizin IV, Nieren- und HochdruckkrankheitenUniversitätsklinikum des SaarlandesHomburg/SaarDeutschland

Personalised recommendations